Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Authors

Mariana Carvalho Gouveia, Pedro José Galvão Freire, Caio Guilherme Souza Prado, Caio Abner Leite, Bruna Migliavacca Zucchetti, Renata Colombo Bonadio, Carlos Barrios, Adriana Kahn, Maryam Lustberg, Romualdo Barroso-Sousa

Published in

Breast (Edinburgh, Scotland). Volume 89. Pages 104853. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

Antibody-drug conjugates (ADCs) have redefined therapeutic paradigms in metastatic breast cancer, offering unprecedented efficacy across hormone receptor-positive/HER2-negative and triple-negative subtypes. Trastuzumab deruxtecan, sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan are expanding treatment options beyond traditional chemotherapy. As their clinical integration advances, optimizing the prevention and management of ADC-related toxicities, determining optimal sequencing strategies, and refining biomarker characterization have become central challenges. Ongoing research into ADC combinations, earlier-line use, and precision biomarker selection is expected to further reshape the therapeutic landscape and personalize care for patients with advanced breast cancer.

PMID:
42398129
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.